Repeat MRI and PSA Screening for Prostate Cancer in Men Previously Screened Negative
Repeats MRI and PSA screening for prostate cancer in men screened negative earlier.
Plain-language title generated from the registry record
Registry title: Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
Key facts
- Where
- Basel, SwitzerlandSee the site
Where in Switzerland
- University Hospital Basel, UrologyBasel, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT07762911
- Record updated
- 13 August 2026
- Original description
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial overdiagnosis and overtreatment of clinically insignificant disease. Biparametric magnetic resonance imaging (bpMRI) has emerged as a promising imaging modality to improve the detection of clinically significant prostate cancer while reducing unnecessary biopsies.Read full original descriptionShow less
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial overdiagnosis and overtreatment of clinically insignificant disease. Biparametric magnetic resonance imaging (bpMRI) has emerged as a promising imaging modality to improve the detection of clinically significant prostate cancer while reducing unnecessary biopsies.
In this prospective follow-up study, men who previously participated in prostate cancer screening and had no evidence of malignancy at baseline will be invited to undergo repeat screening approximately five years later. The study aims to evaluate the longitudinal performance of repeat screening using PSA and MRI, determine the incidence of newly detected clinically significant prostate cancer after an initial negative screening, and assess changes in imaging and clinical findings over time. The results will provide evidence on the value and optimal interval of repeat prostate cancer screening in men with an initially negative evaluation.
Inclusion: "well-informed men" with the wish for prostate cancer screening:; prostate biopsy naïve; life expectancy > 10 years; Paticipant in the VISIONING study.
Exclusion: acute urinary tract infection UTI; life expectancy < 10 years; prostate volume > 80ml; NIH-CPSI score over or equal to19; IPSS score over or equal to 20 (leads to initiation of urologic diagnostics and treatment).